Covid Pan

The summary is as follows:

• Emerging data suggests that the pancreas could be target organ for SARS CoV2 infection with increase in severity of pancreatitis.
• However, there is limited data on the clinical outcomes of patients with co existent SARS- CoV-2 and AP
• Patients with AP and co existent SARS- CoV-2 have a significantly high 30-day inpatient mortality
• These patients also have significantly worse clinical outcomes including risk of developing ARDS, increased severity of pancreatitis, length of stay and organ failure.
• Data from the largest international multicentre study will enable clinicians to better prognosticate for patients with concomitant AP and SARS-CoV-2 infection, optimize resource allocation and target treatment options.

We would like to take this opportunity to thank all the PIs and collaborators across 52 pancreatic units and 8 countries for contributing to the study. This would not have been possible without your hard work and perseverance during one of the most difficult and demanding times in our lifetime.

You can hear about the results in an international COVID PAN webinar on March 23, 2021. Click here for more information and to book

And finally this study would not have been possible without the support of AUGIS; PSGBI; Newcastle upon Tyne Hospitals NHS Foundation Trust & Newcastle University.

Manu Nayar & Sanjay Pandanaboyana on behalf of the COVID PAN collaborative.

Gut Paper

View Resource